Molecular Oncology in Pancreatic Cancer

Overview

Journal J Mol Med (Berl)

Specialty General Medicine

Date 1996 Jun 1

PMID 8862512

Citations 8

Authors

S Gansauge

F Gansauge

H G Beger

Affiliations

Soon will be listed here.

Abstract

Cancer of the pancreas still has a very poor prognosis despite improved diagnostic methods and therapeutic regimens. The reasons for the aggressiveness of this cancer are not known, and the molecular mechanisms that govern the growth of pancreatic cancer cells are still not clearly defined. During the past two decades the development of new molecular biological techniques has offered new perspectives for a better understanding of pancreatic cancer. Tumor markers such as CA19-9 and CEA are used for diagnosis and for following the postoperative course of cancer patients. Characterization of pancreatic cancer cells using several molecular biological techniques has revealed overexpression or altered expression of growth factors and adhesion molecules, implying altered cell-cell and growth-regulatory interactions. In pancreatic cancer mutations in oncogenes and tumor suppressor genes are frequently detected in p53 and K-ras. This article reviews the possible molecular approaches for diagnosis, prognosis, or even therapy of pancreatic cancer.

Citing Articles

Targeted Immunotherapies for Cancers.

Cheung A, Chenoweth A Cancers (Basel). 2024; 16(1).

PMID: 38201439 PMC: 10778418. DOI: 10.3390/cancers16010011.

Tumor Growth Suppression of Pancreatic Cancer Orthotopic Xenograft Model by CEA-Targeting CAR-T Cells.

Sato O, Tsuchikawa T, Kato T, Amaishi Y, Okamoto S, Mineno J Cancers (Basel). 2023; 15(3).

PMID: 36765558 PMC: 9913141. DOI: 10.3390/cancers15030601.

Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions.

Alnefaie A, Albogami S, Asiri Y, Ahmad T, Alotaibi S, Al-Sanea M Front Bioeng Biotechnol. 2022; 10:797440.

PMID: 35814023 PMC: 9256991. DOI: 10.3389/fbioe.2022.797440.

CAR T cells in solid tumors: challenges and opportunities.

Marofi F, Motavalli R, Safonov V, Thangavelu L, Valerievich Yumashev A, Alexander M Stem Cell Res Ther. 2021; 12(1):81.

PMID: 33494834 PMC: 7831265. DOI: 10.1186/s13287-020-02128-1.

The Potential of CAR T Cell Therapy in Pancreatic Cancer.

Akce M, Zaidi M, Waller E, El-Rayes B, Lesinski G Front Immunol. 2018; 9:2166.

PMID: 30319627 PMC: 6167429. DOI: 10.3389/fimmu.2018.02166.

References

Van Waes C, Kozarsky K, WARREN A, Kidd L, Paugh D, Liebert M . The A9 antigen associated with aggressive human squamous carcinoma is structurally and functionally similar to the newly defined integrin alpha 6 beta 4. Cancer Res. 1991; 51(9):2395-402. View

Smith J, Derynck R, Korc M . Production of transforming growth factor alpha in human pancreatic cancer cells: evidence for a superagonist autocrine cycle. Proc Natl Acad Sci U S A. 1987; 84(21):7567-70. PMC: 299340. DOI: 10.1073/pnas.84.21.7567. View

Longenecker B, Willans D, MacLean G, Selvaraj S, Suresh M, Noujaim A . Monoclonal antibodies and synthetic tumor-associated glycoconjugates in the study of the expression of Thomsen-Friedenreich-like and Tn-like antigens on human cancers. J Natl Cancer Inst. 1987; 78(3):489-96. View

Caron de Fromentel C, Soussi T . TP53 tumor suppressor gene: a model for investigating human mutagenesis. Genes Chromosomes Cancer. 1992; 4(1):1-15. DOI: 10.1002/gcc.2870040102. View

Gonzalez A, Buscaglia M, Fox R, Isacchi A, Sarmientos P, Farris J . Basic fibroblast growth factor in Dupuytren's contracture. Am J Pathol. 1992; 141(3):661-71. PMC: 1886703. View

Der C, Cox A . Isoprenoid modification and plasma membrane association: critical factors for ras oncogenicity. Cancer Cells. 1991; 3(9):331-40. View

Neal D, Marsh C, Bennett M, Abel P, Hall R, Sainsbury J . Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours. Lancet. 1985; 1(8425):366-8. DOI: 10.1016/s0140-6736(85)91386-8. View

Warshaw A, Lee K, Wood W, Cohen A . Sensitivity and specificity of serum ribonuclease in the diagnosis of pancreatic cancer. Am J Surg. 1980; 139(1):27-32. DOI: 10.1016/0002-9610(80)90225-1. View

Prins J, De Vries E, Mulder N . Antisense of oligonucleotides and the inhibition of oncogene expression. Clin Oncol (R Coll Radiol). 1993; 5(4):245-52. DOI: 10.1016/s0936-6555(05)80238-9. View

10.

Arnaout M . Structure and function of the leukocyte adhesion molecules CD11/CD18. Blood. 1990; 75(5):1037-50. View

11.

Ruoslahti E . Integrins. J Clin Invest. 1991; 87(1):1-5. PMC: 294975. DOI: 10.1172/JCI114957. View

12.

McKie A, FILIPE M, Lemoine N . Abnormalities affecting the APC and MCC tumour suppressor gene loci on chromosome 5q occur frequently in gastric cancer but not in pancreatic cancer. Int J Cancer. 1993; 55(4):598-603. DOI: 10.1002/ijc.2910550414. View

13.

Levine A, Momand J, Finlay C . The p53 tumour suppressor gene. Nature. 1991; 351(6326):453-6. DOI: 10.1038/351453a0. View

14.

Barton C, Hall P, Hughes C, Gullick W, Lemoine N . Transforming growth factor alpha and epidermal growth factor in human pancreatic cancer. J Pathol. 1991; 163(2):111-6. DOI: 10.1002/path.1711630206. View

15.

GOSPODAROWICZ D, Neufeld G, Schweigerer L . Molecular and biological characterization of fibroblast growth factor, an angiogenic factor which also controls the proliferation and differentiation of mesoderm and neuroectoderm derived cells. Cell Differ. 1986; 19(1):1-17. DOI: 10.1016/0045-6039(86)90021-7. View

16.

Pleskow D, Berger H, Gyves J, Allen E, McLean A, Podolsky D . Evaluation of a serologic marker, CA19-9, in the diagnosis of pancreatic cancer. Ann Intern Med. 1989; 110(9):704-9. DOI: 10.7326/0003-4819-110-9-704. View

17.

Nellen W, Lichtenstein C . What makes an mRNA anti-sense-itive?. Trends Biochem Sci. 1993; 18(11):419-23. DOI: 10.1016/0968-0004(93)90137-c. View

18.

Safi F, Beger H, Bittner R, Buchler M, Krautzberger W . CA 19-9 and pancreatic adenocarcinoma. Cancer. 1986; 57(4):779-83. DOI: 10.1002/1097-0142(19860215)57:4<779::aid-cncr2820570417>3.0.co;2-c. View

19.

Klagsbrun M . The fibroblast growth factor family: structural and biological properties. Prog Growth Factor Res. 1989; 1(4):207-35. DOI: 10.1016/0955-2235(89)90012-4. View

20.

Hruban R, van Mansfeld A, Offerhaus G, van Weering D, Allison D, Goodman S . K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol. 1993; 143(2):545-54. PMC: 1887038. View